References
- Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML) treated with IM. Blood 2009;114(Suppl. 1): Abstract 1126.
- White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761–2767.
- Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;444:879–894.
- Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024–2027.
- Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496–3499.
- Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009;33:271–275.
- Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022–4028.
- Kim D-W, Granvil C, Demirhan E, et al. Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic lyeloid leukemia in chronic phase (CP-CML) treated with 400mg and 800mg daily doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Blood 2009;114(Suppl. 1): Abstract 1127.
- Guilhot F, Hughes TP, Cortes J, et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CP-CML) for 400 mg and 800 mg daily doses (Tyrosine Kinase Dose Optimization Study [TOPS]). Blood 2008;112(Suppl. 1): Abstract 447.
- Liu H, Artz AS. Reduction of imatinib absorption after gastric bypass surgery. Leuk Lymphoma 2010;51, in press.
- Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–2388.
- Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit 2009;31:579–584.
- White DL, Saunders VA, Dang P, et al. CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study. Blood 2008;112(Suppl. 1): Abstract 3187.
- White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064–4072.
- Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758–3765.